What Quell does

Quell is a wearable pain relief technology brand operated by NeuroMetrix, Inc., a wholly-owned subsidiary of electroCore, Inc. since the May 2025 acquisition. The core product is a Transcutaneous Electrical Nerve Stimulation (TENS) device worn on the upper calf that delivers safe, painless electrical impulses to sensory nerves to trigger a natural pain relief response. Quell received FDA 510(k) Clearance (K152954) in 2015, with explicit labeling permitting use during sleep — a regulatory distinction versus standard TENS devices. The portfolio includes the now-discontinued original Quell, the current-generation Quell 2.0 (with smartphone-app-based calibration, sleep, gait, and pain-tracking features), and the prescription-only Quell Fibromyalgia variant targeting fibromyalgia patients. The proprietary dimethylacrylamide-based hydrogel electrode is latex-, BPA-, and phthalate-free, and integrates with Apple Health and Samsung Health for longitudinal data sync.

Quell monetizes via direct-to-consumer hardware sales through its online store and, post-acquisition, through institutional sales into the VA hospital system via parent electroCore's federal healthcare channel. Pricing is not publicly disclosed; a 60-day money-back guarantee is offered. Customer segments are chronic pain patients (consumer) and veterans within the VA healthcare system (institutional). electroCore reported Quell contributed $1.5M in revenue post-acquisition, with the broader company projecting approximately 30% full-year 2026 revenue growth driven by VA penetration and a 93% surge in complementary Truvaga wellness sales. Leadership is in transition: electroCore CEO Daniel Goldberger will retire April 1, 2026, succeeded by COO Michael Fox to leverage federal healthcare expertise. Quell's competitive position rests on its FDA sleep-use clearance, proprietary electrode chemistry, individual calibration, and now its parent's federal-channel reach rather than on AI or software differentiation.

Name

Quell

Legal name

NeuroMetrix, Inc.

Website

https://support.quellrelief.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Quell is a wearable TENS pain relief device brand operated by NeuroMetrix (a subsidiary of electroCore), serving chronic pain patients via DTC online sales and VA hospital system distribution, with FDA clearance for overnight use.

Ownership category

akta.pro rank

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Quell Product Sales: electroCore acquired Quell assets in May 2025, contributing $1.5 million in revenue to the company. The acquisition expanded electroCore's product portfolio within the VA hospital system.
2. Truvaga Wellness Sales: 93% surge in Truvaga wellness sales driven alongside Quell product line expansion in VA hospital system.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Quell designs, manufactures, and sells wearable Transcutaneous Electrical Nerve Stimulation (TENS) devices worn on the upper calf that deliver electrical pulses to sensory nerves to trigger the body's natural pain relief response for chronic pain sufferers. The product portfolio includes the original Quell, the enhanced Quell 2.0, and the prescription-only Quell Fibromyalgia, all FDA 510(k) cleared (K152954) with companion smartphone app integration for therapy, sleep, and gait tracking.

Product overview

Quell is a wearable pain relief technology platform by NeuroMetrix (a wholly-owned subsidiary of electroCore, Inc.) offering transcutaneous electrical nerve stimulation (TENS) devices for chronic pain management. The product portfolio includes the original Quell, Quell 2.0 (enhanced version), and Quell Fibromyalgia (prescription-only variant for fibromyalgia). All devices are worn on the upper calf and work via smartphone app connectivity for calibration, therapy tracking, and sleep monitoring.

Differentiator

Problem solved

Functional benefit

Brands

• Quell 2.0: Second generation wearable pain relief device with advanced calibration and tracking features.
• Quell Fibromyalgia

Products and services

• Quell (original) Original wearable transcutaneous electrical nerve stimulation (TENS) device worn on the upper calf for chronic pain relief, with FDA 510(k) clearance, smartphone app connectivity, sleep tracking, and pain rating features. Listed as Discontinued on the Quell support site.
• Quell 2.0 Enhanced second-generation wearable TENS device for chronic pain management, including app-based calibration, therapy tracking, gait monitoring, sleep position tracking, and repetitive leg movement monitoring.
• Quell Fibromyalgia Prescription-only version of the Quell wearable TENS device specifically indicated for the treatment of fibromyalgia. Available exclusively by prescription through the dedicated quellfibromyalgia.com channel.

Quantifiable outcome

• 93% surge in Truvaga wellness sales
• +2 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Partnerships

One partnership is on record.

• electroCore, Inc.coreStrategic or Co-development PartnerelectroCore, Inc. completed the acquisition of Quell assets in May 2025. Quell assets are now part of electroCore's product portfolio, with NeuroMetrix operating as a wholly-owned subsidiary under electroCore ownership.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Omron Healthcare: Omron manufactures and sells consumer TENS devices such as the Omron Pocket Pain Pro and Electrotherapy Pain Relief units. Direct competitor to Quell in the OTC wearable TENS category for chronic and acute pain.
• Hollywog: Hollywog sells the iTENS, a wireless, app-controlled wearable TENS unit for chronic pain. Highly comparable to Quell in product form factor, app integration, and direct-to-consumer channel.
• BioElectronics Corporation: BioElectronics produces ActiPatch and RecoveryRx, consumer-facing wearable pain relief devices using PEMF and pulsed electromagnetic therapy. Competes with Quell for the same chronic pain consumer looking for non-drug, OTC solutions.
• Cala Health: Cala Health offers Cala Trio, a wearable transcutaneous afferent patterned stimulation (TAPS) device for essential tremor and is expanding into other neurological indications. Closely comparable to Quell as a prescription-grade, app-connected wearable neurostimulator sold outside the hospital.
• ZetrOZ Systems: ZetrOZ Systems sells sam, a wearable, FDA-cleared long-duration ultrasound device for musculoskeletal pain. Comparable to Quell as a non-pharmacological, wearable, app-connected pain relief device targeting chronic pain patients.
• Avacen Medical: Avacen manufactures the Avacen 100, an FDA-cleared noninvasive medical device for chronic pain using thermal stimulation. Comparable to Quell as a non-drug, non-implantable, in-home pain relief device.

Broad incumbents

• Chattanooga (DJO Global / Enovis): Chattanooga, part of Enovis (formerly DJO), is a long-standing manufacturer of clinical and consumer TENS/EMS units including the Intelect series. Overlaps with Quell in TENS technology but operates across a broader portfolio of orthopedic rehab and pain management products.
• SPR Therapeutics: SPR Therapeutics commercializes the Sprint PNS system, a minimally invasive peripheral nerve stimulation platform for chronic and post-surgical pain. Comparable to Quell as a neuromodulation-based pain therapy, though SPR is implant-procedure-based while Quell is fully external.
• electroCore: electroCore is Quell's parent company following the May 2025 asset acquisition and sells gammaCore (nVNS) for headache and other indications. Relevant as the strategic acquirer and channel provider, with overlapping non-invasive neuromodulation positioning.

Emerging players

• Saluda Medical: Saluda Medical is developing the Evoke closed-loop spinal cord stimulation system for chronic pain. Comparable to Quell as a chronic-pain neuromodulation competitor, though Saluda is an implantable SCS player versus Quell's transcutaneous approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quell